Once you know what makes you itch, sneeze, wheeze, or break out in spots, ALK-Abelló can prepare a vaccine for you. With subsidiaries and facilities in 15 countries, ALK-Abelló is a leading producer of allergy vaccination and diagnostic pharmaceuticals and the EpiPen brand of adrenaline for emergency use during severe allergy allergic. Involved in the development of allergy vaccinations since 1923, ALK-Abelló is expanding its products to orally delivered vaccinations as well as subcutaneous (injected) vaccinations. It is developing natural allergens in tablet form to fight grass pollen and house dust mites.
Financial data as of December 31, 2019 (12 month period) in USD
Dun & Bradstreet collects private company financials for more than 23 million companies in over 200 countries. Find out more.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
- EMPLOYEES (This Site) 750
- ASSETS (MIL USD) 813
- SALES (MIL USD) 484.68
- TICKER SYMBOL ALK B
- FISCAL YEAR END DEC
- SALES GROWTH % 12.32%
Get in Touch with 10 Contacts
Carsten HellmannManaging Director
Katja BarnkobStaff representative on the board
Jakob RiisBoard Member